Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jonathan Mow
AddedMar 31, 2024
UpdatedMay 1, 2026
Jonathan Mow

Jonathan Mow

CEO, PhaseBio Pharmaceuticals

Jonathan Mow's Career

PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals

Malvern, PA, US

CEO· C-Suite · Management
Veralox Therapeutics
Veralox Therapeutics

Frederick, MD, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jonathan Mow's Career

PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals
Public$324.3M402002Malvern, PA, US
CEO· C-Suite · Management

Leadership at PhaseBio Pharmaceuticals

Alex SapirAlex SapirBoard Member
Richard Van Den BroekRichard Van Den BroekBoard Member
Clay ThorpClay ThorpBoard Member
Justin KleinJustin KleinBoard Member
Bill HumphriesBill HumphriesBoard Member
Caroline LoewyCaroline LoewyBoard Member

Similar to PhaseBio Pharmaceuticals

CiVi BiopharmaCiVi BiopharmaChevy Chase, MD, USBiopharmaceuticalsest. 2016CiVi BiopharmaChevy Chase, MD, US · est. 2016

CiVi Biopharma: A US-based biotech firm specializing in R&D for cardiovascular and metabolic diseases.

Public · $89M14
BridgeBio PharmaBridgeBio PharmaPalo Alto, CA, USGenetic Medicinesest. 2015BridgeBio PharmaPalo Alto, CA, US · est. 2015

Bridgebio Pharma, a US-based biotech firm, specializes in developing medicines for genetic diseases globally.

Public · $3.6B392
Kyntra BioKyntra BioSan Francisco, CA, USPharmaceuticalsest. 1993Kyntra BioSan Francisco, CA, US · est. 1993

FibroGen, Inc: A global, research-based pharmaceutical company in San Francisco, innovating treatments for unmet medical needs.

Public · $188M592
Longevity BiotechLongevity BiotechPhiladelphia, PA, USDrug Candidates, Therapeuticsest. 2010Longevity BiotechPhiladelphia, PA, US · est. 2010

Philadelphia-based Longevity Biotech develops Hybridtides, transformative products tackling medical challenges.

Angel · $1.9M6
Veralox Therapeutics
Veralox Therapeutics
Series B$47.5M172018Frederick, MD, US
CEO· C-Suite · Management

Leadership at Veralox Therapeutics

Jeffrey W. StrovelJeffrey W. StrovelCo-Founder
Ben ScruggsBen ScruggsBoard Member
David MaloneyDavid MaloneyCo-Founder
Alex MartinAlex MartinBoard Member
Matthew B. BoxerMatthew B. BoxerCo-Founder
Anand PadmanabhanAnand PadmanabhanBoard Member

Jonathan Mow's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder & CEO · DiDiHong Eun-taekHong Eun-taekCEO · KakaoChoi Soo-yeonChoi Soo-yeonCEO · NaverMickey MikitaniMickey MikitaniCEO · RakutenKoji ShibataKoji ShibataCEO · ANA HoldingsNobuo HayasakaNobuo HayasakaCEO · KioxiaTaek-Jin KimTaek-Jin KimCo-Founder & CEO · Ncsoft

People Similar to Jonathan Mow

Jim LousararianJim LousararianCEO · Verax BiomedicalMitch SteinerMitch SteinerCEO · VeruRenato CataldoRenato CataldoCEO · Verax Research ServicesJohn EdwardsJohn EdwardsCEO · Verseau TherapeuticsNick ColangeloNick ColangeloBoard Member · VericelTed WhiteTed WhiteCEO · Verrica Pharmaceuticals